Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome

Pharmacogenetics and Genomics

Volumn 24, Issue 1, 2014, Pages 1-5

  Dávila Fajardo, Cristina L ^a   Márquez, Ana ^a   Pascual Salcedo, Dora ^b   Moreno Ramos, Manuel J ^c   García Portales, Rosa ^d   Magro, César ^a   Alegre Sancho, Juan J ^e   Balsa, Alejandro ^b   Cabeza Barrera, José ^a   Raya, Enrique ^a   Martín, Javier ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Antitumor necrosis factor; Interleukin 6; Pharmacogenetics; Rheumatoid arthritis; Single nucleotide polymorphism

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6;

ADULT; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; SPAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOSINE; FEMALE; GENETIC MARKERS; GENOTYPE; GUANINE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891025987     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000013     Document Type: Article

References (33)

1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-442. (Pubitemid 46834849)
2. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFNgamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-279. (Pubitemid 41577417)
3. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
4. Elliott MJ,Woo P, Charles P, Long-Fox A,Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factoralpha (cA2). Br J Rheumatol 1997; 36: 589-593.
5. Maini R St, Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
6. Hyrich KL,Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-1565. (Pubitemid 44817065)
7. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681. (Pubitemid 38296553)
8. Umicevic MM, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR, et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1375-1381.
9. Tak PP. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) 2012; 51: 600-609.
10. Barnes TC, Spiller DG, Anderson ME, Edwards SW, Moots RJ. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? Ann Rheum Dis 2011; 70: 366-372.
11. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-542.
12. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183: 3170-3176.
13. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374 (Pt 1): 1-20. (Pubitemid 37046923)
14. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005; 23: 1-21. (Pubitemid 40563163)
15. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376. (Pubitemid 28467565)
16. Pascual M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000; 1: 338-340.
17. Jenny NS, Tracy RP, Ogg MS, Luong lA, Kuller LH, Arnold AM, et al. In the elderly, interleukin-6 plasma levels and the - 174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22: 2066-2071. (Pubitemid 36025216)
18. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-2265. (Pubitemid 32433715)
19. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, et al. Interleukin-6 gene - 174g> c and - 572g >c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458-1463. (Pubitemid 34219808)
20. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, et al. Association of interleukin-6 (IL-6) - 174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204: 178-183.
21. Jancic I, Arsenovic-Ranin N, Sefik-Bukilica M, Zivojinovic S, Damjanov N, Spasovski V, et al. - 174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int 2013; 33: 1481-1486.
22. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40. (Pubitemid 26036375)
23. Van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996; 35 (Suppl 2): 4-7.
24. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
25. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995; 45: 486-490.
26. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980; 32: 5-338.
27. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992; 19: 22-25.
28. Drynda S, Kuhne C, Kekow J. Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis 2002; 61: 254-256. (Pubitemid 34177758)
29. Zivojinovic SM, Pejnovic NN, Sefik-Bukilica MN, Kovacevic LV, Soldatovic II, Damjanov NS. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis. J Rheumatol 2012; 39: 18-21.
30. Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol 2013; 40: 1074-1081.
31. Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R, et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012; 22: 577-589.
32. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, et al. Genomewide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008; 14 (9-10): 575-581.
33. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011; 63: 645-653.